Fantastic news for patients with DLBCL. Congrats to @DocHutchings and colleagues
Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. nej.md/3PdaABZView quoted post on X